- Conditions
- Hemophilia B
- Interventions
- IB1001
- Biological
- Lead sponsor
- Cangene Corporation
- Industry
- Eligibility
- 12 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 265–288
of 322
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hemophilia A
- Interventions
- rAHF-PFM
- Drug
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- Male only
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Duarte, California + 30 more
- Conditions
- Congenital Bleeding Disorder, Haemophilia A
- Interventions
- turoctocog alfa
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- Up to 11 Years · Male only
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Orange, California • Torrance, California + 15 more
- Conditions
- Hemophilia A
- Interventions
- BAY94-9027
- Biological
- Lead sponsor
- Bayer
- Industry
- Eligibility
- Up to 12 Years · Male only
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 7
- States / cities
- Sacramento, California • Pensacola, Florida • Cincinnati, Ohio + 4 more
- Conditions
- Hemophilia A, Hemophilia B
- Interventions
- Ataluren
- Drug
- Lead sponsor
- PTC Therapeutics
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 7
- States / cities
- Peoria, Illinois • Indianapolis, Indiana • Worcester, Massachusetts + 4 more
- Conditions
- Hemophilia A
- Interventions
- Not listed
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 1 Day to 99 Years · Male only
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hematologic Disease, Hemophilia A
- Interventions
- Kogenate (BAY14-2222)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 30 Years to 45 Years · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Chapel Hill, North Carolina • Houston, Texas
- Conditions
- Severe Hemophilia A
- Interventions
- rFVIIIFc
- Biological
- Lead sponsor
- Bioverativ Therapeutics Inc.
- Industry
- Eligibility
- 12 Years and older · Male only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Salt Lake City, Utah • Seattle, Washington
- Conditions
- Hemophilia A, Congenital
- Interventions
- Alphanate
- Biological
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- Up to 12 Years · Male only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 8
- States / cities
- Atlanta, Georgia • Lexington, Kentucky • Minneapolis, Minnesota + 5 more
- Conditions
- Factor VIII Deficiency, Congenital
- Interventions
- Emicizumab
- Drug
- Lead sponsor
- Indiana Hemophilia &Thrombosis Center, Inc.
- Other
- Eligibility
- 5 Years to 45 Years · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Hemophilia
- Interventions
- Coagulation Factor VIIa (Recombinant)
- Biological
- Lead sponsor
- Laboratoire français de Fractionnement et de Biotechnologies
- Industry
- Eligibility
- 6 Months to 75 Years · Male only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Hemophilia a, Hemophilia B
- Interventions
- No Intervention
- Other
- Lead sponsor
- ApcinteX Ltd
- Industry
- Eligibility
- 12 Years to 65 Years · Male only
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 2
- States / cities
- Ann Arbor, Michigan • Greenville, South Carolina
- Conditions
- Hemophilia A With Inhibitor, Haemophilia A Without Inhibitor, Hemophilia B With Inhibitor, Haemophilia B Without Inhibitor
- Interventions
- Not listed
- Lead sponsor
- American Thrombosis and Hemostasis Network
- Network
- Eligibility
- Not listed
- Enrollment
- 395 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 29
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Diego, California + 23 more
- Conditions
- Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
- Interventions
- Concizumab, Eptacog alfa
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Indianapolis, Indiana • Iowa City, Iowa
- Conditions
- Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
- Interventions
- The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 0 Years to 20 Years
- Enrollment
- 5,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2026
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
- Conditions
- Congenital Bleeding Disorder, Haemophilia B
- Interventions
- nonacog beta pegol
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 13 Years to 70 Years · Male only
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Jacksonville, Florida • Augusta, Georgia + 9 more
- Conditions
- Hemophilia A
- Interventions
- NXT007, Emicizumab
- Combination Product · Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 10
- States / cities
- Orange, California • Aurora, Colorado • Miami, Florida + 7 more
- Conditions
- Hemophilia A, Immune Tolerance
- Interventions
- FVIII, Emicizumab
- Drug
- Lead sponsor
- Children's Hospital Los Angeles
- Other
- Eligibility
- 0 Years to 12 Years · Male only
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Hemophilia B
- Interventions
- PF-06838435 (formerly SPK-9001)
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 17
- States / cities
- Sacramento, California • Metairie, Louisiana • New Orleans, Louisiana + 4 more
- Conditions
- Hemophilia A With Inhibitors
- Interventions
- Factor VIII concentrates, Low-dose treatment, High-dose treatment
- Drug · Other
- Lead sponsor
- New York Presbyterian Hospital
- Other
- Eligibility
- Up to 7 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2012
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Duarte, California • Orange, California + 31 more
- Conditions
- Hemophilia A
- Interventions
- Blood sample collection
- Procedure
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 186 participants
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Significant Bleeding Risk
- Interventions
- Octaplex, Beriplex P/N (Kcentra)
- Drug
- Lead sponsor
- Octapharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 208 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 22
- States / cities
- Aurora, Colorado • New Haven, Connecticut • Miami, Florida + 14 more
- Conditions
- Hemophilia A
- Interventions
- Antihemophilic factor, recombinant, manufactured protein-free
- Drug
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 7 Years to 65 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 6 more
- Conditions
- Hemophilia B
- Interventions
- Not listed
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 3
- States / cities
- Little Rock, Arkansas • Gainesville, Florida • Ann Arbor, Michigan